Neurophet

Neurophet Gross Margin

The Gross Margin of Neurophet (380550.KQ) as of Oct 15, 2026 is 100.00 %. In the previous year, Gross Margin was 100.00 % — a change of 0.00% (lower).

Gross Margin

100.00 %

YoY

0.00%

Last updated:

Gross Margin of Neurophet is 2025 100.00 % . Gross Margin of Neurophet was 2024 100.00 % . It decreases by 0.00% lower compared to the previous year.

For Neurophet, the gross margin of 100.0% is down versus 102.5% a few years ago.

The Neurophet Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2022
102.53 KRW
Jan 1, 2023
91.47 KRW
Jan 1, 2024
100.00 KRW
Jan 1, 2025
100.00 KRW
The Neurophet Gross Margin history
YEARGross MarginYoY
100.00 %0.00%
100.00 %+9.33%
91.47 %-10.79%
102.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neurophet Stock analysis

What does Neurophet do? Neurophet Inc is a South Korean company operating in the Health Care sector, headquartered in Seoul. The company has 135 employees and is listed on the Korean stock exchange with the ticker 380550.KQ and ISIN KR7380550004. Neurophet Inc went public on July 25, 2025, marking its initial public offering. The company focuses on the research, development, and sales of brain imaging analysis software, including PET image quantitative analysis software called 'Neurophet SCALE PET' and neurodegenerative brain disease diagnosis support software named 'Neurophet AQUA'. Additionally, Neurophet Inc develops and sells therapeutic medical devices and provides medical artificial intelligence solutions. The company's website is https://www.neurophet.com/. Neurophet Inc operates within the Health Care Technology industry, specializing in software and AI-driven tools for medical imaging and diagnostics. The company's products are designed to support healthcare professionals in analyzing brain imaging data and diagnosing neurological conditions. As a technology-focused health care provider, Neurophet Inc aims to enhance diagnostic accuracy and efficiency through its software solutions. The company's operations are based in Seoul, South Korea, and it is engaged in both the development and commercialization of its medical technology products. Neurophet Inc's business model centers on creating innovative software tools that address specific challenges in neurology and brain imaging analysis. Neurophet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neurophet stock

Gross Margin of Neurophet is 100.00 % in 2025.

Gross Margin of Neurophet changed from 100.00 % to 100.00 %, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Neurophet since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Neurophet with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Neurophet

All Key Metrics — Neurophet